Passa al contenuto
Merck
Tutte le immagini(1)

Documenti fondamentali

Visualizza tutta la documentazione

E9658

Sigma-Aldrich

Enalaprilat dihydrate

≥98% (HPLC)

Sinonimo/i:

(2S)-1-[(2S)-2-[[(1S)-1-Carboxy-3-phenyl-propyl]amino]propanoyl]pyrrolidine-2-carboxylic acid, Vasotec

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali

Scegli un formato

5 MG
127,00 €
25 MG
538,00 €

127,00 €

Per informazioni sulla disponibilità, contatta il Servizio Clienti.
Richiedi un ordine bulk
Tutte le immagini(1)

Scegli un formato

Cambia visualizzazione
5 MG
127,00 €
25 MG
538,00 €

About This Item

Formula empirica (notazione di Hill):
C18H24N2O5 ·2H2O
Numero CAS:
84680-54-6
Peso molecolare:
384.42
Numero CE:
278-459-3
Numero MDL:
MFCD00941393
Codice UNSPSC:
12352200
ID PubChem:
329799089
NACRES:
NA.77

127,00 €

Per informazioni sulla disponibilità, contatta il Servizio Clienti.
Richiedi un ordine bulk

Saggio

≥98% (HPLC)

Solubilità

H2O: 14 mg/mL at 60 °C (warming for 5 minutes)
DMSO: 64 mg/mL

Ideatore

Merck & Co., Inc., Kenilworth, NJ, U.S.

Temperatura di conservazione

room temp

Stringa SMILE

O.O.C[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N2CCC[C@H]2C(O)=O

InChI

1S/C18H24N2O5.2H2O/c1-12(16(21)20-11-5-8-15(20)18(24)25)19-14(17(22)23)10-9-13-6-3-2-4-7-13;;/h2-4,6-7,12,14-15,19H,5,8-11H2,1H3,(H,22,23)(H,24,25);2*1H2/t12-,14-,15-;;/m0../s1
MZYVOFLIPYDBGD-MLZQUWKJSA-N

Informazioni sul gene

human ... ACE(1636)

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Azioni biochim/fisiol

Enalapril, the ethyl ester of enalaprilat exhibits slight pharmacological activity until it is hydrolyzed in the liver to enalaprilat.[1] Enalaprilat, a IV form of an angiotensin-converting-enzyme inhibitor (ACE) prevents the transformation of angiotensin I to angiotensin II, a potent vasoconstrictor.[2]
Enalaprilat is an inhibitor of angiotensin converting enzyme (ACE), antihypertensive, and a Bradykinin B1 receptor activator.
Enalaprilat is an inhibitor of angiotensin converting enzyme (ACE), antihypertensive, and a Bradykinin B1 receptor activator. Enalaprilat has nM potency versus ACE and also activates B1 receptors to release NO.

Caratteristiche e vantaggi

This compound is featured on the Angiotensin Receptors and Bradykinin Receptors pages of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Merck & Co., Inc., Kenilworth, NJ, U.S.. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Codice della classe di stoccaggio

11 - Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Dispositivi di protezione individuale

Eyeshields, Gloves, type N95 (US)

Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number
0000205055
0000205056
0000205056
0000205055
0000193594

Non trovi la versione di tuo interesse?

Se hai bisogno di una versione specifica, puoi cercare il certificato tramite il numero di lotto.

Cerca un COA

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Slide 1 of 4

1 of 4

Lisinopril ≥98% (HPLC)

Sigma-Aldrich

L6292

Lisinopril

Irbesartan ≥98% (HPLC), powder

Sigma-Aldrich

I2286

Irbesartan

Captopril ≥98% (HPLC), powder

Sigma-Aldrich

C4042

Captopril

1,10-Phenanthroline ≥99%

Sigma-Aldrich

131377

1,10-Phenanthroline

Fabio Mangiacapra et al.
Journal of the American College of Cardiology, 61(6), 615-621 (2013-01-08)
This study investigated the influence of intracoronary enalaprilat on coronary microvascular function and peri-procedural outcome measures in patients with stable angina undergoing percutaneous coronary intervention (PCI). Intracoronary angiotensin-converting enzyme inhibitors have been shown to relieve myocardial ischemia in stable patients
Fredrik Palm et al.
Hypertension (Dallas, Tex. : 1979), 55(2), 298-304 (2010-01-06)
Angiotensin II maintains renal cortical blood flow and renal oxygenation in the clipped kidney of early 2-kidney, 1-clip Goldblatt hypertensive (2K,1C) rats. The involvement of Ang II is believed to decline, whereas oxidative stress increases during the progression of 2K,1C
Chinmoy Ghosh et al.
Drug testing and analysis, 4(2), 94-103 (2011-02-23)
A rapid and most sensitive method for simultaneous determination of enalapril (ENP) and its metabolite, enalaprilat (ENPT), in human plasma using ESI-LC-MS/MS (electrospray ionization liquid chromatography tandem mass spectrometry) positive ion multiple reactions monitoring (MRM) mode, was developed and validated.
Min Yu et al.
Molecules (Basel, Switzerland), 17(3), 2738-2751 (2012-03-08)
Enalaprilat (Ena.), an angiotensin II (Ang II) converting enzyme inhibitor (ACEI), can produce some therapeutic effects on hypertension, ventricular hypertrophy and myocardial remodeling in clinic, but its precise mechanism, especially its signaling pathways remain elusive. In this study, cardiac fibroblasts
J G Kingma et al.
Experimental physiology, 96(12), 1293-1301 (2011-09-06)
Myocardial perfusion and contraction are closely coupled; however, the effect of recurrent no-flow ischaemia on perfusion-contraction matching remains to be established. In the present studies, we examined the influence of modulating nitric oxide availability on perfusion-contraction matching after recurrent no-flow
Visualizza tutti i documenti correlati

Articoli

Angiotensin Receptors

We offer many products related to angiotensin receptors for your research needs.

Domande

Recensioni

Nessuna valutazione

Filtri attivi

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.